Specific antidotes for bleeding associated with direct oral anticoagulants

BMJ. 2017 May 25:357:j2216. doi: 10.1136/bmj.j2216.

Authors

Allison Burnett^{1

2}, Deborah Siegal³, Mark Crowther⁴

Affiliations

¹ University of New Mexico Hospital, Albuquerque, New Mexico, USA aburnett@salud.unm.edu.
² University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA.
³ Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
⁴ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 28546438
DOI: 10.1136/bmj.j2216

No abstract available

MeSH terms

Administration, Oral
Antibodies, Monoclonal, Humanized / economics
Antibodies, Monoclonal, Humanized / therapeutic use
Anticoagulants / administration & dosage
Anticoagulants / adverse effects*
Coagulants / economics
Coagulants / therapeutic use*
Hemorrhage / chemically induced*
Hemorrhage / drug therapy*
Humans

Substances

Antibodies, Monoclonal, Humanized
Anticoagulants
Coagulants
idarucizumab